I 
119TH CONGRESS 
1ST SESSION H. R. 2756 
To authorize the National Biotechnology Initiative, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 9, 2025 
Mrs. BICE (for herself and Mr. KHANNA) introduced the following bill; which 
was referred to the Committee on Science, Space, and Technology, and 
in addition to the Committees on Foreign Affairs, Agriculture, Energy 
and Commerce, and Education and Workforce, for a period to be subse-
quently determined by the Speaker, in each case for consideration of such 
provisions as fall within the jurisdiction of the committee concerned 
A BILL 
To authorize the National Biotechnology Initiative, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘National Biotechnology 
Initiative Act of 2025’’. 
SEC. 2. DEFINITIONS. 
In this Act: 
(1) BIOLITERACY.—The term ‘‘bioliteracy’’ re-
fers to the concept of imbuing people, personnel, or 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
teams with an understanding of and ability to en-
gage with biology and biotechnology. 
(2) BIOLOGICAL DATA.—The term ‘‘biological 
data’’ means the information, including associated 
descriptors, derived from the structure, function, or 
process of a biological system(s) that is either meas-
ured, collected, or aggregated for analysis. 
(3) 
BIOMANUFACTURING.—The 
term 
‘‘bio-
manufacturing’’ means the application of bio-
technology to manufacturing. 
(4) 
BIOTECHNOLOGY.—The 
term 
‘‘bio-
technology’’ means the application of science and en-
gineering in the direct or indirect use of living orga-
nisms, or parts or products of living organisms, in-
cluding modified forms. 
(5) 
DIRECTOR
OF
THE
NATIONAL
BIO-
TECHNOLOGY
COORDINATION
OFFICE.—The term 
‘‘Director of the National Biotechnology Coordina-
tion Office’’ means the individual appointed pursu-
ant to section 4(b)(2)(A). 
(6) INITIATIVE.—The term ‘‘Initiative’’ means 
the National Biotechnology Initiative established 
under section 3. 
(7) 
INTERAGENCY
COMMITTEE.—The 
term 
‘‘Interagency Committee’’ means the interagency 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
committee 
designated 
pursuant 
to 
section 
10403(a)(1). 
(8) OFFICE.—The term ‘‘Office’’ means the 
National Biotechnology Coordination Office estab-
lished under section 4(b). 
(9) PARTICIPATING AGENCY.—The term ‘‘par-
ticipating agency’’ means a department, office, or 
agency set forth under section 3(b). 
SEC. 
3. 
AUTHORIZATION 
OF 
THE 
NATIONAL 
BIO-
TECHNOLOGY INITIATIVE. 
(a) INITIATIVE REQUIRED.— 
(1) 
IN
GENERAL.—The 
President, 
acting 
through the Executive Office of the President, shall 
implement an initiative to advance national security, 
economic productivity, and competitiveness through 
advancement and coordination of Federal activities 
relating to biotechnology. 
(2) DESIGNATION.—The initiative implemented 
pursuant to paragraph (1) shall be known as the 
‘‘National Biotechnology Initiative’’. 
(b) PARTICIPATING AGENCIES.—The following shall 
be participants in the Initiative: 
(1) The Department of Agriculture. 
(2) The Department of Commerce. 
(3) The Department of Defense. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(4) The Department of Energy. 
(5) The Department of Health and Human 
Services. 
(6) The Department of Homeland Security. 
(7) The Department of the Interior. 
(8) The Department of State. 
(9) The Environmental Protection Agency. 
(10) The National Aeronautics and Space Ad-
ministration. 
(11) The National Science Foundation. 
(12) The Office of the Director of National In-
telligence. 
(13) The Office of the United States Trade 
Representative. 
(14) Such other Federal departments and agen-
cies as the Director of the National Biotechnology 
Coordination Office considers appropriate. 
(c) ACTIVITIES.—Each head of a participating agen-
cy shall carry out the Initiative, including by carrying out 
the activities required by section 6 and by addressing and 
coordinating the following: 
(1) Federal activities relating to biotechnology, 
including to create and maintain a national strategy 
on biotechnology. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(2) National security implications of emerging 
biotechnology. 
(3) Sustained support for research and develop-
ment that accelerates scientific understanding and 
technological innovation in biotechnology. 
(4) Sustained support for biological data, data-
bases, and related tools as a strategic national re-
source. 
(5) Private sector translation and commer-
cialization of products that are produced with bio-
technology. 
(6) Regulatory streamlining for products that 
are produced with biotechnology. 
(7) Biosafety and biosecurity issues associated 
with emerging biotechnology. 
(8) Development of a domestic workforce, in-
cluding the Federal workforce, to advance bio-
technology across the United States. 
(9) Bioliteracy activities that provide clear, 
easy-to-find 
information 
for 
policymakers, 
innovators, and the public. 
(10) International partnerships, including regu-
latory and commercial diplomacy. 
(11) Such other activities relating to bio-
technology as the Director of the National Bio-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
technology Coordination Office and the Interagency 
Committee jointly determine are needed to advance 
national security, economic productivity, and com-
petitiveness relating to biotechnology. 
SEC. 4. INITIATIVE COORDINATION. 
(a) INTERAGENCY COMMITTEE.— 
(1) DESIGNATION.—Not later than 180 days 
after the date of the enactment of this Act, the 
President shall, acting through the Executive Office 
of the President, designate an interagency committee 
to coordinate activities of the Initiative. 
(2) DUTIES.—Each member of the Interagency 
Committee shall— 
(A) work with the Director of the National 
Biotechnology Coordination Office to oversee 
the planning, management, and coordination of 
the Initiative; 
(B) ensure the department or agency of 
the member supports the Initiative through rel-
evant activities set forth under section 6; 
(C) keep the other members of the Inter-
agency Committee apprised of the activities de-
scribed in subparagraph (B); and 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(D) communicate activities of the Inter-
agency Committee with relevant components of 
the Department or agency of the member. 
(3) 
MEMBERSHIP.—The 
Interagency 
Com-
mittee shall include 1 member at the Assistant Sec-
retary level from each participating agency selected 
by the head of the participating agency. 
(4) CO-CHAIRPERSONS.— 
(A) IN GENERAL.—The Interagency Com-
mittee shall have 3 co-chairpersons, of whom— 
(i) one co-chairperson shall be the Di-
rector of the National Biotechnology Co-
ordination Office; and 
(ii) two co-chairpersons shall be se-
lected by the members of the Interagency 
Committee from among the members of 
the Interagency Committee. 
(B) TERMS.—Each co-chairperson selected 
pursuant to subparagraph (A)(ii) shall serve a 
term of 2 years, except for the first term the 
Interagency Committee shall select one co- 
chairperson to serve a term of 3 years, such 
that subsequent terms are staggered. 
(C) VACANCIES.— 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(i) IN
GENERAL.—A vacancy under 
this paragraph shall be filled in the man-
ner in which the original appointment was 
made and shall be subject to any condi-
tions that applied with respect to the origi-
nal appointment. 
(ii) FILLING UNEXPIRED TERM.—An 
individual chosen to fill a vacancy shall be 
appointed for the unexpired term of the co- 
chairperson replaced. 
(D) QUORUM.—A majority of the members 
of the Interagency Committee shall constitute a 
quorum for the purposes of voting for co-chair-
persons under clauses (i)(II) and (ii)(II) of sub-
paragraph (A), with co-chairpersons selected by 
the member who receives the highest plurality 
of votes. 
(E) LIMITATION.—A member of the Inter-
agency Committee from a particular Federal 
department or agency may not serve consecu-
tive terms as co-chairperson of the Interagency 
Committee. 
(b) NATIONAL BIOTECHNOLOGY COORDINATION OF-
FICE.— 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(vi) utilize, with their consent, the 
services, personnel, and facilities of other 
Federal agencies; and 
(vii) accept voluntary and uncompen-
sated services, notwithstanding the provi-
sions of section 1342 of title 31, United 
States Code. 
(3) FUNCTIONS
OF
THE
OFFICE.—The func-
tions of the Office shall be, in support of the Initia-
tive, the following: 
(A) PLANNING
AND
COORDINATION.— 
Functions relating to planning and coordination 
as follows: 
(i) Working with the Interagency 
Committee to oversee the planning, man-
agement, and coordination of Federal ac-
tivities relating to biotechnology. 
(ii) Providing technical and adminis-
trative support to the Interagency Com-
mittee. 
(iii) Assessing the landscape and gaps 
associated with the different components of 
the Initiative. 
(iv) Coordinating a fellowship pro-
gram in which Federal employees are de-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
tailed to 1 or more Federal agencies to 
gain 
greater 
understanding 
of 
bio-
technology activities outside of their home 
agency. 
(v) Building and maintaining a co-
ordinated website for Federal activities re-
lating to biotechnology pursuant to sub-
section (c). 
(vi) Coordinating development of an 
annual report under subsection (d) and a 
national strategy as required by subsection 
(e). 
(vii) Conducting such other activities 
to support the Initiative as the Director 
considers appropriate. 
(B) NATIONAL SECURITY.—Functions re-
lating to national security as follows: 
(i) Assessing and addressing the na-
tional security and economic security impli-
cations of emerging biotechnology. 
(ii) Identifying and remedying any 
major needs or information gaps in current 
national security assessments and activi-
ties, including to conduct counterintel-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
ligence efforts to fill gaps relating to bio-
technology. 
(iii) Providing coordination in ad-
dressing foreign investments and acquisi-
tion from adversarial countries. 
(C) RESEARCH
AND
DEVELOPMENT.— 
Functions relating to research and development 
as follows: 
(i) Coordinating sustained support for 
research and development that accelerates 
scientific understanding and technological 
innovation in biotechnology. 
(ii) Facilitating joint agency solicita-
tions for funding for individual grants, col-
laborative grants, and interdisciplinary re-
search centers. 
(iii) Developing and proposing focus 
areas or challenges for research funding 
meant to advance biotechnology, particu-
larly relating to convergence with other 
technologies such as artificial intelligence. 
(iv) Developing, standardizing, and 
deploying robust mechanisms for docu-
menting and quantifying the outputs and 
economic benefits of biotechnology. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(D) DATA
AND
DATABASES.—Functions 
relating to data and databases as follows: 
(i) Coordinating sustained support for 
biological data, databases, and related 
tools as a strategic national resource to ad-
vance human health and the understanding 
of animals, plants, microbes, and other or-
ganisms. 
(ii) Recommending actions to inte-
grate security into biological data access 
and international reciprocity agreements. 
(iii) Coordinating frameworks for bio-
logical data standardization to create 
datasets that are interoperable and usable 
by advanced computation methods such as 
artificial intelligence. 
(E) 
PRODUCT
COMMERCIALIZATION.— 
Functions relating to product commercialization 
as follows: 
(i) Strategizing and coordinating on 
private sector translation and commer-
cialization of products that are produced 
with biotechnology. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(ii) Assisting in coordinating a na-
tional network of testbeds to enable scale- 
up of biotechnology research. 
(F) REGULATORY STREAMLINING.—Func-
tions relating to regulatory streamlining as fol-
lows: 
(i) Coordinating the easing of regu-
latory burden for types of biotechnology 
products that have become well-understood 
by regulators, including products that 
could have occurred naturally or been de-
veloped with conventional means. 
(ii) Negotiating interagency agree-
ments that describe clear regulatory path-
ways for each type of biotechnology prod-
uct, with information about timelines, deci-
sion points, expected data requirements, 
clear hand-offs between agencies, and 
other information deemed necessary by the 
Office to resolve regulatory gaps, overlaps, 
and ambiguities for biotechnology prod-
ucts. 
(iii) Providing regular status updates 
to the Office of Management and Budget 
as to the development of clear regulatory 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
pathways, and in the event that the Office 
and the Interagency Committee cannot 
reach timely agreement on a clear regu-
latory pathway for any product type, as-
sisting the Director of the Office of Man-
agement and Budget in carrying out para-
graph (5). 
(iv) Not later than 1 year after the 
date of the enactment of this Act, jointly 
with the Interagency Committee developing 
and making available to the public a plan 
for regulatory streamlining. 
(G) BIOSAFETY AND BIOSECURITY.—Func-
tions relating to biosafety and biosecurity as 
follows: 
(i) Developing strategies and coordi-
nating to address biosafety and biosecurity 
issues 
associated 
with 
emerging 
bio-
technology. 
(ii) Coordinating on assessment and 
mitigation of potential biosafety and bio-
security threats relating to biotechnology 
research, including through collaboration 
with regulatory agencies and industry. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(H) WORKFORCE
DEVELOPMENT.—Func-
tions relating to workforce development as fol-
lows: 
(i) Coordinating and developing strat-
egies to develop a domestic workforce for 
biotechnology. 
(ii) Coordinating with appropriate 
agencies to establish a national bio-
technology workforce framework to define 
biotechnology jobs and skills in public and 
private sectors. 
(iii) Coordinating with appropriate 
agencies to conduct an interagency assess-
ment of biotechnology workforce needs, 
and subsequently developing and providing 
training programs. 
(I) BIOLITERACY.—Functions relating to 
bioliteracy as follows: 
(i) Coordinating development of plain- 
language materials about biotechnology. 
(ii) Providing central locations, includ-
ing the website required by subsection (c), 
for clear, easy-to-find information about 
biotechnology for policymakers, innovators, 
and the public. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(J) 
INTERNATIONAL
PARTNERSHIPS.— 
Functions relating to international partnerships 
as follows: 
(i) Coordinating Federal regulatory 
and commercial diplomacy activities. 
(ii) Assessing the current regulatory 
and commercial diplomacy activities car-
ried out across the Federal Government, 
identifying gaps, and developing an out-
reach strategy to improve the regulatory 
landscape and market access for products 
of the United States. 
(iii) Identifying non-regulatory solu-
tions for trade and market access concerns 
(such as the use of identity preservation 
for certain agricultural biotechnology prod-
ucts) and working with relevant govern-
ment agencies and stakeholders to imple-
ment solutions. 
(K) OTHER.—Such other activities as the 
Director considers necessary to advance na-
tional security, economic productivity, and com-
petitiveness related to biotechnology. 
(4) ADMINISTRATIVE
SUPPORT
AND
AUTHOR-
IZATION OF APPROPRIATIONS.— 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(A) ADMINISTRATIVE SUPPORT.—The Di-
rector of the National Science Foundation shall 
provide support for the administration and im-
plementation of the Initiative, including— 
(i) appointing and providing com-
pensation for employees of the Office, with-
out regard to any provision relating to ap-
pointment or compensation under title 5, 
United States Code, including— 
(I) deputy directors as needed to 
address the responsibilities in para-
graph (3), as determined necessary by 
the Director of the Office; and 
(II) other appropriate employees, 
including experts in the science of bio-
technology, biotechnology policy, regu-
latory policy, and science communica-
tion, legal counsel, and software de-
signers and developers, as determined 
necessary by the Director of the Of-
fice; 
(ii) fixing the compensation of employ-
ees of the Office in an amount that does 
not exceed the amount of annual com-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
pensation (excluding expenses) specified in 
section 102 of title 3, United States Code; 
(iii) detailing employees of the Na-
tional Science Foundation to the Office 
and receiving the detail of employees from 
other agencies to the Office; and 
(iv) assistance with other costs associ-
ated with running the Initiative, including 
physical space, other staff, and overhead 
support. 
(B) 
AUTHORIZATION
OF
APPROPRIA-
TIONS.—There are authorized to be appro-
priated to the Director of the National Science 
Foundation to carry out subparagraph (A)— 
(i) $22,000,000 for fiscal year 2026; 
(ii) $35,000,000 for fiscal year 2027; 
(iii) $25,000,000 for fiscal year 2028; 
(iv) $25,000,000 for fiscal year 2029; 
and 
(v) $25,000,000 for fiscal year 2030. 
(5) REGULATORY STREAMLINING BY OFFICE OF 
MANAGEMENT AND BUDGET.—In the event that the 
Office and the Interagency Committee cannot reach 
timely agreement on a clear regulatory pathway for 
a 
product 
type, 
as 
described 
in 
paragraph 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(3)(F)(iii), the Director of the Office of Management 
and Budget shall— 
(A) identify overlaps, gaps, or ambiguities 
in the regulation for such product type; 
(B) negotiate an interagency agreement 
that describes a clear regulatory pathway for 
such product type, with information about 
timelines, decision points, expected data re-
quirements, clear hand-offs between agencies, 
and other information deemed necessary by the 
Office of Management and Budget to resolve 
regulatory gaps, overlaps, and ambiguities; and 
(C) recommend and oversee rulemaking or 
changes to guidance as needed to implement 
clear regulatory pathways. 
(6) WIND-DOWN.— 
(A) IN GENERAL.—The Office shall wind- 
down its activities on the date that is 20 years 
after the date of the enactment of this Act, and 
transition to serving as an executive secretariat 
for the Initiative. 
(B) WIND-DOWN ACTIVITIES.—The activi-
ties specified in this clause are as follows: 
(i) The transfer of authorities, re-
quirements, resources, personnel, and obli-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
gations of the Office to the fullest extent 
possible to the Interagency Committee and 
such elements of the Federal Government 
as the Director and the Interagency Com-
mittee considers appropriate. 
(ii) The Office shall maintain authori-
ties, requirements, resources, personnel, 
and obligations necessary to serve as the 
executive secretariat for the Initiative, in-
cluding to continue the coordination in 
subsection (b)(3)(A), the website in sub-
section (c), and any other activities that 
the Director and the Interagency Com-
mittee considers appropriate. 
(C) TREATMENT OF TRANSFERRED FUNC-
TIONS.—Commencing on the date on which the 
Office is terminated under subparagraph (A), 
any reference to a requirement or an authority 
of the Office that has been transferred to the 
Interagency Committee or an element of the 
Federal Government shall be treated as a ref-
erence to the Interagency Committee or the ele-
ment of the Federal Government to which such 
requirement or authority was transferred pursu-
ant to subparagraph (B). 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(c) WEBSITE.— 
(1) IN
GENERAL.—Not later than 540 days 
after the date of the enactment of this Act, the Di-
rector of the National Biotechnology Coordination 
Office and the Interagency Committee shall jointly 
develop and publish for the public a single, coordi-
nated Federal website for biotechnology that adheres 
to best practices for website design, development, 
and maintenance. 
(2) CONTENTS.—The website developed and 
published pursuant to paragraph (1) shall include 
the following: 
(A) A dashboard of Federal Government 
activities relating to biotechnology, including in-
formation about open funding opportunities. 
(B) Plain-language information about bio-
technology, including information for policy-
makers, innovators, trading partners, and the 
public. 
(C) A mechanism for stakeholders to ask a 
question and receive a single, coordinated re-
sponse. 
(D) Mechanisms, which may be populated 
over time, to provide consolidated information 
about biotechnology product regulation, focus-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
ing on products that are regulated by more 
than 1 Federal agency, with content that in-
cludes the following: 
(i) A repository of interagency agree-
ments that describe clear regulatory path-
ways, with links to relevant regulations 
and guidance documents for each type of 
biotechnology product. 
(ii) A repository of regulatory decision 
documents for biotechnology products. 
(iii) A digital portal that allows sub-
mission of a single application and infor-
mation sharing between Federal agencies. 
(3) UPDATES.—The Director and the Inter-
agency Committee shall jointly update the website 
required by paragraph (1) periodically. 
(d) ANNUAL REPORTS.— 
(1) IN GENERAL.—Not later than 1 year after 
the date of the enactment of this Act, and not less 
frequently than once each year thereafter, except in 
years in which a national strategy for biotechnology 
is required under subsection (e), the Director of Na-
tional Biotechnology Coordination Office and the 
Interagency Committee shall jointly submit to the 
Committee on Commerce, Science, and Transpor-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
tation of the Senate and the Committee on Science, 
Space, and Technology of the House of Representa-
tives an annual report on the Initiative. 
(2) CONTENTS.—Each annual report submitted 
pursuant to paragraph (1) shall include, for the pe-
riod covered by the report, the following: 
(A) An inventory and accounting of Fed-
eral Government activities and spending in sup-
port of the Initiative. 
(B) Actions that the Director and the 
Interagency Committee plan to take in support 
of the Initiative in the next fiscal year. 
(e) NATIONAL STRATEGY.— 
(1) IN GENERAL.—Not later than 2 years after 
the date of the enactment of this Act, and not less 
frequently than once every 5 years thereafter, the 
Director of National Biotechnology Coordination Of-
fice and the Interagency Committee shall jointly 
make available to the public and submit to the Com-
mittee on Commerce, Science, and Transportation of 
the Senate and the Committee on Science, Space, 
and Technology of the House of Representatives a 
comprehensive national strategy for biotechnology. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(2) ELEMENTS.—Each national strategy made 
available and submitted pursuant to paragraph (1) 
shall cover the following: 
(A) Actions, goals, and priorities to ad-
vance the Initiative, including how each Federal 
department and agency will address the require-
ments of section 6 and how each Federal de-
partment 
and 
agency 
will 
integrate 
bio-
technology into their own strategies. 
(B) Activities that are an urgent priority 
to advance biotechnology in the United States 
but not currently being conducted by Federal 
agencies, with an estimated 5-year budget for 
those activities. 
(C) Recommendations for legislative or ad-
ministrative action to advance biotechnology in 
the United States. 
(D) An inventory of all Federal Govern-
ment databases with biological data with an as-
sessment that identifies opportunities— 
(i) to improve the utility of such data-
bases, in a manner that does not com-
promise national security or the privacy 
and security of information within such 
databases; and 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(ii) to inform investment in such data-
bases as critical infrastructure for the bio-
technology research enterprise. 
(E) An assessment of United States com-
petitiveness in biotechnology relative to peer 
countries, including— 
(i) contributions of biotechnology to 
United States economic growth and other 
societal indicators; 
(ii) contributions of biotechnology to 
economic growth in other countries, espe-
cially peer-competitors; and 
(iii) current barriers to commercializa-
tion of biotechnology products, processes, 
and tools in the United States. 
(F) A national biological data strategy to 
ensure biotechnology research fully leverages 
plant, animal, and microbe biodiversity, as ap-
propriate and in a manner that does not com-
promise economic competitiveness, national se-
curity, or the privacy or security of human ge-
netic information. 
(G) The information that is required as a 
part of the annual report required by subsection 
(d). 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(f) COMPTROLLER GENERAL REVIEW.—The Comp-
troller General of the United States shall— 
(1) not later than 3 years after the date of the 
enactment of this Act, begin a review to assess the 
efficacy of interagency coordination and fulfillment 
of the activities conducted by the Office and the 
Interagency Committee under the Initiative; 
(2) not later than 3.5 years after the date of 
the enactment of this Act, provide Congress a brief-
ing on the initial findings of the Comptroller General 
with respect to the activities described in paragraph 
(1); 
(3) not later than 4 years after the date of the 
enactment of this Act, submit to the Committee on 
Commerce, Science, and Transportation of the Sen-
ate and the Committee on Science, Space, and Tech-
nology of the House of Representatives a report with 
recommendations to improve the Initiative; and 
(4) repeat the process outlined in paragraphs 
(1), (2), and (3) every 5 years thereafter until the 
date that is 20 years after the date of the enactment 
of this Act. 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 5. CONVENING OF EXPERTS ON BIOTECHNOLOGY RE-
SEARCH AND DEVELOPMENT. 
(a) IN GENERAL.—The Director of the National Bio-
technology Coordination Office may, in consultation with 
the Interagency Committee, convene experts to assess and 
inform the activities of the Initiative in a time and manner 
as deemed appropriate and necessary by the Director. 
(b) APPLICATION
OF FEDERAL ADVISORY COM-
MITTEE ACT.—Section 1013 of title 5, United States 
Code, shall not apply to the convening of experts under 
this section. 
SEC. 6. AGENCY ACTIVITIES. 
Each head of a participating agency shall, in support 
of the Initiative and in coordination with the Office, con-
duct or support, in a manner consistent with the duties 
and mission of the respective department or agency, the 
following activities to advance biotechnology across de-
fense, human health, food and agriculture, energy, space, 
mining, environmental stewardship, and other sectors: 
(1) PLANNING AND COORDINATION.—Activities 
relating to planning and coordination as follows: 
(A) Designating an individual within the 
respective department or agency at the level of 
Assistant Secretary to lead the biotechnology 
activities for the department or agency, if such 
person is not already designated, and to serve 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
as the department or agency liaison to the Ini-
tiative and member of the Interagency Com-
mittee. 
(B) Designating individuals within the re-
spective department or agency to serve as mem-
bers of subcommittees that may be established 
by the Interagency Committee. 
(C) Coordinating activities of the partici-
pating agency that relate to biotechnology with 
the Office. 
(D) Implementing applicable portions of 
the national strategy required by section 4(e) in 
ways that improve government efficiency and 
reduce redundancy. 
(E) Providing insight and information 
about biotechnology to the heads of other Fed-
eral departments and agencies and to Congress. 
(F) Leveraging horizon scanning and tech-
nology foresight to ensure United States leader-
ship in future biotechnology advancements. 
(2) NATIONAL SECURITY.—Activities relating to 
national security as follows: 
(A) Analyzing ongoing and emerging 
threats from foreign adversary development and 
application of biotechnology, including foreign 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
investments and acquisition of United States 
capabilities, technologies, and biological data. 
(B) Providing expertise to address foreign 
investments and acquisition from adversarial 
countries. 
(C) Analyzing and identifying actions to 
mitigate supply chain risks posed by foreign ad-
versary involvement in such supply chains. 
(D) Coordinating and ensuring information 
sharing with foreign service officers regarding 
threats to and opportunities for biotechnology. 
(E) Coordinating with industry on threat 
information sharing, vulnerability disclosure, 
and risk mitigation for cybersecurity and infra-
structure risks, including risks to biological 
data and related physical and digital infrastruc-
ture and devices. 
(F) Improving cybersecurity and stress- 
testing related to sensitive biological data and 
to biotechnology infrastructure, tools, and in-
strumentation. 
(3) RESEARCH AND DEVELOPMENT.—Activities 
relating to research and development as follows: 
(A) Providing sustained support for re-
search and development that accelerates sci-
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
entific understanding and technological innova-
tion in biotechnology. 
(B) Conducting joint agency solicitation 
and selection of applications for funding of indi-
vidual grants, collaborative grants, and inter-
disciplinary research centers. 
(C) Developing instrumentation, equip-
ment, and infrastructure for biotechnology, in-
cluding to optimize, standardize, scale, and de-
liver new products and solutions. 
(D) Developing standard reference mate-
rials and measurements to promote interoper-
ability between new component technologies and 
processes for biotechnology discovery, innova-
tion, and production processes. 
(E) Increasing understanding of the risks 
and benefits of biotechnology, including how 
products developed with biotechnology can af-
fect or protect the environment. 
(F) Increasing understanding of the eth-
ical, legal, and social implications of bio-
technology, including research that contributes 
to public understanding of biotechnology. 
(4) DATA AND DATABASES.—Activities relating 
to data and databases as follows: 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(A) Providing sustained support for bio-
logical data, databases, and related tools to ad-
vance human health and the understanding of 
animals, plants, microbes, and other organisms. 
(B) Establishing, curating, and maintain-
ing genomics, epigenomics, and other relevant 
omics and biological data and databases, such 
as through a centralized biological data access 
hub with appropriate protections for the privacy 
or security of information within such data-
bases. 
(C) Developing standards for biological 
data and databases, including for curation, 
interoperability, and protection of privacy and 
security. 
(D) Developing computational tools, in-
cluding artificial intelligence tools, to accelerate 
research and innovation using biological data 
and databases. 
(E) Developing tools that use omics and 
associated bioinformatic sciences to improve 
monitoring, management, assessments, and 
forecasts. 
(5) PRODUCT COMMERCIALIZATION.—Activities 
relating to product commercialization as follows: 
VerDate Sep 11 2014 
02:08 Apr 24, 2025
Jkt 059200
PO 00000
Frm 00033
Fmt 6652
Sfmt 6201
E:\BILLS\H2756.IH
H2756
kjohnson on DSK7ZCZBW3PROD with $$_JOB